Verapamil and risk of cancer in patients with coronary artery disease
| Autor: | Hans Henrik Storm, Ahmad Sajadieh, Jørgen Fischer Hansen |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
medicine.medical_specialty
Chemotherapy education.field_of_study Framingham Risk Score business.industry medicine.medical_treatment Population Cancer Infarction medicine.disease Placebo Coronary artery disease Internal medicine cardiovascular system medicine Cardiology Verapamil Cardiology and Cardiovascular Medicine business education medicine.drug |
| Zdroj: | The American Journal of Cardiology. 83:1419-1422 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/s0002-9149(99)00113-7 |
| Popis: | The risk of cancer in users of verapamil was assessed in a long-term follow-up of 1,775 patients who were randomized to verapamil or matching placebo in the Danish Verapamil Infarction Trial-II in the years 1985 to 1987. During 10,474 patient-years, no increased risk of cancer was observed for the verapamil-treated men or women compared with the age- and sex-matched background population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect